secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2025-03-12T23:59:59+00:00
Accession:  0001104659-25-023015
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Pharma enters $10M secured credit agreement with Innoviva at 14% p.a., matures March 2026
--------------------------------------------------------------------------------

- $10 million term loan from Innoviva at 14.0% annual interest, secured by substantially all assets.
- Loan matures March 12, 2026; proceeds to fund development of phage candidates AP-PA02 and AP-SA02.
- Amendments extend maturity of three prior Innoviva credit agreements also to March 12, 2026.
- Innoviva is Armata's largest shareholder; loan guaranteed by domestic subsidiaries.
- Company pursuing additional non-dilutive funding for late-stage trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/0001104659-25-023015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/tm258929d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-023015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer